Evidence map›Paper›PMID 9271121›Full record

ArticleGenes & development1997

PPARgamma induces cell cycle withdrawal: inhibition of E2F/DP DNA-binding activity via down-regulation of PP2A.

S Altiok, M Xu, B M Spiegelman

Open access · diamondAbstract read
In one paragraph

Article in Genes & development, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 106 papers.

0numbers the graph read from it
0cells of the map it votes in
106citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

106 citing papers in PubMed, 380 citations in OpenAlex.

  1. Trial
  2. Protein phosphatase 2A impairs cardiac uptake of glucose in the mammalian heart.Naunyn-Schmiedeberg's archives of pharmacology · 2026
    Article
  3. Review
  4. Article
  5. Article
  6. Effects ofAnimals : an open access journal from MDPI · 2022
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. PPAR-PPAR research · 2019
    Article
  14. Article
  15. Article
  16. Transcriptomics Analysis of the Chinese Pear Pathotype ofInternational journal of molecular sciences · 2018
    Article
  17. Article
  18. Noncanonical agonist PPARγ ligands modulate the response to DNA damage and sensitize cancer cells to cytotoxic chemotherapy.Proceedings of the National Academy of Sciences of the United States of America · 2018
    Article
  19. Article
  20. Article

46 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

S AltiokDana-Farber Cancer Institute and the Department of Cell Biology, Harvard Medical School, Boston, Massachusetts 02115, USA.
M Xu
B M Spiegelman
Harvard University · USDana-Farber Cancer Institute · US

Funding

CONTROL OF ADIPOCYTE GENE EXPRESSION AND PHYSIOLOGYR37DK031405 · NIDDK · DANA-FARBER CANCER INSTITUTE · PI SPIEGELMAN, BRUCE M. · 1996 to 2013
$8.2M
CONTROL OF LIPOGENIC ENZYME SYNTHESIS IN ADIPOCYTESR01DK031405 · NIDDK · DANA-FARBER CANCER INSTITUTE · PI SPIEGELMAN, BRUCE M. · 1986 to 2018
$2.9M
NIDDK NIH HHS DK31405NIDDK NIH HHS R01 DK031405NIDDK NIH HHS R37 DK031405
6 · The paper itself

Abstract

PPAR gamma is an adipose-selective nuclear hormone receptor that plays a key role in the control of adipocyte differentiation. Previous studies indicated that activation of ectopically expressed PPAR gamma induces differentiation when cells have ceased growth because of confluence. We show here that ligand activation of PPAR gamma is sufficient to induce growth arrest in fibroblasts and SV40 large T-antigen transformed, adipogenic HIB1B cells. Cell cycle withdrawal is accompanied by a decrease in the DNA-binding and transcriptional activity of the E2F/DP complex, which is attributable to an increase in the phosphorylation of these proteins, especially DP-1. This effect is a consequence of decreased expression of the catalytic subunit of the serine-threonine phosphatase PP2A. These data suggest an important role for PP2A in the control of E2F/DP activity and a new mode of cell cycle control in differentiation.

Indexed as

Carrier ProteinsCell Cycle ProteinsThiazolidinediones3T3 CellsAdipocytesAnimalsCell CycleCell Line, TransformedDNA-Binding ProteinsE2F Transcription FactorsLigandsMicePhosphoprotein PhosphatasesPhosphorylationPioglitazoneReceptors, Cytoplasmic and NuclearArid4a protein, mouseCarrier ProteinsCell Cycle ProteinsDNA-Binding ProteinsE2F Transcription FactorsLigandsPhosphoprotein PhosphatasesPioglitazoneReceptors, Cytoplasmic and NuclearRetinoblastoma-Binding Protein 1RNA, MessengerTfdp1 protein, mouseThiazolesThiazolidinedionesTranscription Factor DP1Transcription Factors

Identifiers

PMID9271121
PMCPMC316411
OpenAlexW2103633745

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.